NasdaqCM - Delayed Quote USD

Anebulo Pharmaceuticals, Inc. (ANEB)

2.8500 -0.0400 (-1.38%)
At close: April 18 at 4:00 PM EDT
2.7300 -0.12 (-4.21%)
After hours: April 18 at 7:34 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Joseph F. Lawler M.D., Ph.D. Founder & Chairman 11k -- 1972
Dr. Kenneth C. Cundy Ph.D. Chief Scientific Officer 425.15k -- 1959
Mr. Richard Anthony Cunningham CEO & Director -- -- 1971
Mr. Daniel V. George Principal Accounting Officer, Acting CFO & Secretary -- -- 1970
Mr. Scott L. Anderson Head of Investor Relations & Public Affairs -- -- --

Anebulo Pharmaceuticals, Inc.

1017 Ranch Road 620 South
Suite 107
Lakeway, TX 78734
United States
(512) 598-0931 https://www.anebulo.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
2

Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.

Corporate Governance

Anebulo Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 09, 2024 - May 13, 2024
Anebulo Pharmaceuticals, Inc. Earnings Call

Related Tickers

GNTA Genenta Science S.p.A.
3.9156
+20.85%
 
7PO.SG Poxel SA
0.6290
+8.26%
 
ENGNW enGene Holdings Inc.
4.1400
-3.72%
 
NVCT Nuvectis Pharma, Inc.
6.72
-0.59%
 
NAMSW NewAmsterdam Pharma Company N.V.
9.30
+1.09%
 
SXTP 60 Degrees Pharmaceuticals, Inc.
0.2464
-1.44%
 
LIPO Lipella Pharmaceuticals Inc.
0.7133
-0.01%
 
OPT Opthea Limited
3.4000
-0.58%
 
LABP Landos Biopharma, Inc.
21.75
+0.23%
 
ICCC ImmuCell Corporation
5.05
0.00%